About Cofactor Genomics
Cofactor Genomics is a company based in San Francisco (United States) founded in 2009. Cofactor Genomics has raised $26.2 million across 7 funding rounds from investors including Leland Stanford Junior University, Wilson Sonsini Goodrich & Rosati and HHS. The company has 9 employees as of December 31, 2022. Cofactor Genomics has completed 1 acquisition, including Narus Biotechnologies. Cofactor Genomics offers products and services including OncoPrism and ImmunoPrism. Cofactor Genomics operates in a competitive market with competitors including Veracyte, Cajal Neuroscience, HAYA Therapeutics, Alida Biosciences and Novigenix, among others.
- Headquarter San Francisco, United States
- Employees 9 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cofactor Genomics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$26.2 M (USD)
in 7 rounds
-
Latest Funding Round
Not available
-
Investors
Leland Stanford Junior University
& 9 more
-
Employee Count
9
as on Dec 31, 2022
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cofactor Genomics
Cofactor Genomics offers a comprehensive portfolio of products and services, including OncoPrism and ImmunoPrism.
Predicts patient response to cancer immunotherapy via RNA analysis
Assesses immune responses for clinical research and diagnostics
People of Cofactor Genomics
Unlock access to complete
Unlock access to complete
Funding Insights of Cofactor Genomics
Cofactor Genomics has successfully raised a total of $26.2M across 7 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cofactor Genomics
Cofactor Genomics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Leland Stanford Junior University, Wilson Sonsini Goodrich & Rosati and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage venture capital firm investing in AI, healthcare, and tech sectors.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Strategic investments in healthcare technologies and data innovations.
|
Locked | Locked | Locked |
Investor details for Cofactor Genomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cofactor Genomics
Cofactor Genomics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Narus Biotechnologies.
Investment portfolio details for Cofactor Genomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
RNA-based diagnostic tests for neurological disorders are developed.
|
Locked | Locked | 2015 | Locked |
Complete acquisition details for Cofactor Genomics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Cofactor Genomics
Detailed financials for Cofactor Genomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cofactor Genomics Comparisons
Peer comparison for Cofactor Genomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cofactor Genomics
Cofactor Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Veracyte, Cajal Neuroscience, HAYA Therapeutics, Alida Biosciences and Novigenix, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are developed.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease drugs are developed through genetic screening and multi-omics.
|
|
| Locked | Locked | Locked |
RNA-based therapies for treating heart diseases are developed.
|
|
| Locked | Locked | Locked |
Technology for RNA analysis is provided to advance human health.
|
|
| Locked | Locked | Locked |
Immuno-transcriptomic technology for cancer precision medicine is developed.
|
Detailed competitors of Cofactor Genomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cofactor Genomics
Complete news archive for Cofactor Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cofactor Genomics
Cofactor Genomics was founded in 2009 and raised its 1st funding round 5 years after it was founded.
Cofactor Genomics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Cofactor Genomics is a funded company, having raised a total of $26.2M across 7 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Cofactor Genomics is 9.
Developer of diagnostic assays using RNA sequencing. The companys product includes ImmunoPrism is an RNA sequencing-based assay that uses predictive immune modeling to generate multidimensional biomarkers. It combines machine learning and RNA-sequencing to build gene expression models for immune cells. The companys models for key immune cells include Immune Health Expression Models, Immune Escape Genes, and Co-inhibitory molecules. The companys sequencing products include mRNAble, Total RNAble, picoRNA, FFPExact, miRNAble, RNAccess, RNAmplify, and RNAdvantage.
Cofactor Genomics's top competitors include HAYA Therapeutics, Veracyte and Alida Biosciences.
Cofactor Genomics offers OncoPrism and ImmunoPrism.
Cofactor Genomics has made 1 acquisition, including Narus Biotechnologies.
Cofactor Genomics has 10 investors. Key investors include Leland Stanford Junior University, Wilson Sonsini Goodrich & Rosati, HHS, Menlo Ventures, and DCVC.